Published online before print December 13, 2004, doi: 10.1161/01.CIR.0000150391.38660.9B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:3842-3848.)
© 2004 American Heart Association, Inc.
Vascular Medicine |
Multiple Abnormalities in Glucose and Energy Metabolism and Coordinated Changes in Levels of Adiponectin, Cytokines, and Adhesion Molecules in Subjects With Metabolic Syndrome
From the Departments of Medicine (U.S., E.R., J.P., I.V., M.L.), Radiology (S.K.), Clinical Chemistry (K.P.), and Clinical Physiology and Nuclear Medicine (E.V.), University of Kuopio, Kuopio, Finland.
Correspondence to Markku Laakso, MD, Professor and Chair, Department of Medicine, University of Kuopio, 70210 Kuopio, Finland. E-mail markku.laakso{at}kuh.fi
Received June 24, 2004; revision received August 3, 2004; accepted August 4, 2004.
Background— Detailed metabolic defects in glucose and energy metabolism and abnormalities in a variety of cardiovascular risk factors are largely unknown in subjects with the metabolic syndrome.
Methods and Results— We characterized the metabolic syndrome in 119 nondiabetic offspring of diabetic probands. Cardiovascular risk factors, including cytokines and adhesion molecules, were measured. Insulin sensitivity was assessed by the euglycemic hyperinsulinemic clamp and indirect calorimetry; intra-abdominal fat and subcutaneous fat were assessed by CT; and maximal oxygen consumption was measured with a bicycle ergometer test. By applying factor analysis, we identified a single factor, the metabolic syndrome factor, from the following variables: 2-hour glucose, fasting insulin, body mass index, waist, HDL cholesterol, triglycerides, and mean blood pressure. Subjects with the highest factor score were defined as having the metabolic syndrome. During hyperinsulinemia, the highest factor score was associated with decreased rates of glucose oxidation and nonoxidative glucose disposal, high rates of lipid oxidation, low energy expenditure, and impaired suppression of free fatty acids during hyperinsulinemia. Furthermore, the metabolic syndrome was associated with a high amount of visceral fat, hypoadiponectinemia, a low maximum oxygen uptake, and high levels of C-reactive protein, proinflammatory cytokines, and adhesion molecules.
Conclusions— The metabolic syndrome is characterized by an excess of intra-abdominal fat, hypoadiponectinemia, insulin resistance in skeletal muscle and adipose tissue, multiple defects in glucose and energy metabolism, and elevated levels of cytokines and adhesion molecules.
Key Words: adiponectin • cell adhesion molecules • cytokines • insulin resistance • metabolic syndrome X
This article has been cited by other articles:
 |
|
 |
|
  V Bellomio, A Spindler, E Lucero, A Berman, R Sueldo, H Berman, M Santana, M. Molina, V Gongora, G Cassano, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus Lupus, October 1, 2009; 18(11): 1019 - 1025. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Aizawa, J. K. Shoemaker, T. J. Overend, and R. J. Petrella Metabolic syndrome, endothelial function and lifestyle modification Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 181 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. ALZadjali, V. Godfrey, F. Khan, A. Choy, A. S. Doney, A. K. Wong, J. R. Petrie, A. D. Struthers, and C. C. Lang Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J. Am. Coll. Cardiol., March 3, 2009; 53(9): 747 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Herder, E. J. Brunner, W. Rathmann, K. Strassburger, A. G. Tabak, N. C. Schloot, and D. R. Witte Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes: The Whitehall II Study Diabetes Care, March 1, 2009; 32(3): 421 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel The Metabolic Syndrome Endocr. Rev., December 1, 2008; 29(7): 777 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Saltevo, M. Vanhala, H. Kautiainen, and M. Laakso Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 328 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Liu, R. Retnakaran, A. Hanley, R. Tungtrongchitr, C. Shaw, and G. Sweeney Total and High Molecular Weight But Not Trimeric or Hexameric Forms of Adiponectin Correlate with Markers of the Metabolic Syndrome and Liver Injury in Thai Subjects J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4313 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Zivkovic, J B. German, and A. J Sanyal Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease Am. J. Clinical Nutrition, August 1, 2007; 86(2): 285 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Q. Shaibi, M. L. Cruz, M. J. Weigensberg, C. M. Toledo-Corral, C. J. Lane, L. A. Kelly, J. N. Davis, C. Koebnick, E. E. Ventura, C. K. Roberts, et al. Adiponectin Independently Predicts Metabolic Syndrome in Overweight Latino Youth J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1809 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Liu, J.-H. Chen, L.-J. Lin, and J. K. Liao Increased Rho Kinase Activity in a Taiwanese Population With Metabolic Syndrome J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1619 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Santaniemi, Y A. Kesaniemi, and O. Ukkola Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur. J. Endocrinol., November 1, 2006; 155(5): 745 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms Circulation, April 18, 2006; 113(15): 1888 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Matsushita, H. Yatsuya, K. Tamakoshi, K. Wada, R. Otsuka, S. Takefuji, K. Sugiura, T. Kondo, T. Murohara, and H. Toyoshima Comparison of Circulating Adiponectin and Proinflammatory Markers Regarding Their Association With Metabolic Syndrome in Japanese Men Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 871 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. X. Pi-Sunyer, L. J. Aronne, H. M. Heshmati, J. Devin, J. Rosenstock, and for the RIO-North America Study Group Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial JAMA, February 15, 2006; 295(7): 761 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pladevall, B. Singal, L. K. Williams, C. Brotons, H. Guyer, J. Sadurni, C. Falces, M. Serrano-Rios, R. Gabriel, J. E. Shaw, et al. A Single Factor Underlies the Metabolic Syndrome: A confirmatory factor analysis Diabetes Care, January 1, 2006; 29(1): 113 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Tuttle Renal manifestations of the metabolic syndrome Nephrol. Dial. Transplant., May 1, 2005; 20(5): 861 - 864. [Full Text] [PDF]
|
|